<DOC>
	<DOCNO>NCT00517283</DOCNO>
	<brief_summary>As exenatide slow rate material leave stomach , likely alter rate intestinal absorption oral drug administer within certain timeframe relative exenatide . In addition , residence time within stomach medication may prolong data study help assess change residence time presence therapeutic dos exenatide . This study also evaluate relationship blood level exenatide parameter measure rate stomach emptying .</brief_summary>
	<brief_title>A Study Scintigraphy Evaluate Effect Exenatide Gastric Emptying Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Subjects least 1 year history type 2 diabetes mellitus . Subjects control oral antidiabetic agent diet exercise demonstrate screen HbA1c ≥7.0 % ≤10.0 % . Between body mass index ( BMI ) 19 kg/m2 40 kg/m2 , inclusive . Within 4 month initial dose study drug , receive drug receive regulatory approval indication . Persons previously complete withdrawn study study investigate exenatide . Subjects use drug significantly affect gastrointestinal motility ( include acarbose , metoclopramide , macrolide antibiotic ) . Subjects intend start new concomitant medication study , include overthe counter medication , apart occasional intake paracetamol vitamin/mineral supplement . Antiemetic medication may permit investigator 's discretion , except affect gastrointestinal motility . Subjects use insulin 4 week within 3 month prior screen . Blood donation 500 mL last 3 month screen blood donation within last month .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>gastric empty</keyword>
	<keyword>exenatide</keyword>
	<keyword>Byetta</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>